Headline: AngioDynamics (ANGO) Secures FDA IDE for NanoKnife BPH Study

AngioDynamics (ANGO) secured FDA approval for its Investigational Device Exemption (IDE) for the RELIEF study on June 18, 2026. This pivotal study will evaluate the NanoKnife System as a treatment for benign prostatic hyperplasia (BPH). The approval marks a significant step towards expanding NanoKnife's market beyond its current oncology indications. The RELIEF study is designed as a prospective, multi-center, randomized controlled trial. If successful, it could position the NanoKnife System as a minimally invasive option for BPH, a condition affecting millions of men globally. The study's outcome could significantly impact AngioDynamics' future revenue streams. NanoKnife currently holds FDA 510(k) clearance for soft tissue ablation, primarily used in oncology. Expanding into the BPH market could substantially broaden its addressable market and diversify the company's product applications beyond its current focus.